Skip to main content
Weekly Report

Weekly Sepsis Research Analysis

Week 42, 2025
3 papers selected
3 analyzed

This week’s sepsis literature converged on three domains: mechanistic immunometabolism/epigenetics with actionable targets (e.g., GFAT–DRP1–calcium axis, histone lactylation/PAD4, TGFBI), randomized evidence refining resuscitation paradigms (TARTARE-2S showing no advantage for lower-MAP tissue-perfusion targeting but acceptable safety), and large-scale surveillance/diagnostic advances (regional AMR burden forecasts, high-performing EHR prediction models, and rapid point-of-care assays). Together

Summary

This week’s sepsis literature converged on three domains: mechanistic immunometabolism/epigenetics with actionable targets (e.g., GFAT–DRP1–calcium axis, histone lactylation/PAD4, TGFBI), randomized evidence refining resuscitation paradigms (TARTARE-2S showing no advantage for lower-MAP tissue-perfusion targeting but acceptable safety), and large-scale surveillance/diagnostic advances (regional AMR burden forecasts, high-performing EHR prediction models, and rapid point-of-care assays). Together these studies shift emphasis toward time-sensitive interventions, host-directed therapeutics, and improved diagnostic/stewardship infrastructure.

Selected Articles

1. Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics.

82.5
Clinical science (London, England : 1979) · 2025PMID: 41082631

In murine polymicrobial sepsis models and complementary in vitro assays, glutamine supplementation restored macrophage bacterial phagocytosis, lowered bacterial burden, modulated cytokines, and improved survival. Mechanistically, glutamine activated a GFAT-dependent program that promoted DRP1 oligomerization (via O-GlcNAcylation) and CDK1-dependent DRP1 Ser616 phosphorylation, enhancing mitochondrial fission, mitochondrial Ca2+ efflux, and sustained cytosolic calcium needed for phagocytosis.

Impact: Identifies a novel, druggable immunometabolic axis (GFAT–DRP1–calcium) linking nutrient signaling to macrophage function with in vivo survival benefit, reframing glutamine from a nutritional supplement to a mechanistically supported adjunctive immunorestorative candidate.

Clinical Implications: Supports prioritized translational work: define timing/dose and safety of glutamine in immunosuppressed sepsis phenotypes, develop pharmacodynamic biomarkers (O-GlcNAcylation, DRP1 phosphorylation), and explore small-molecule modulators of GFAT/DRP1 in early-phase trials.

Key Findings

  • Glutamine supplementation restored macrophage phagocytosis and improved survival in polymicrobial sepsis mice; benefits abrogated by macrophage depletion.
  • Mechanism: GFAT-dependent O-GlcNAcylation drove DRP1 oligomerization and GFAT–CDK1 signaling induced DRP1 Ser616 phosphorylation, promoting mitochondrial fission and mitochondrial Ca2+ efflux to sustain cytosolic Ca2+ for phagocytosis.
  • Provides in vivo and mechanistic evidence linking immunometabolism to host defense and identifies measurable pathway biomarkers.

2. Targeted Tissue Perfusion Versus Macrocirculatory-Guided Standard Care in Patients With Septic Shock: A Randomized Clinical Trial-The TARTARE-2S Trial.

81
Critical care medicine · 2025PMID: 41105050

In a multicenter randomized trial (n=219) of septic shock patients with lactate >3 mmol/L, a strategy targeting bedside tissue perfusion while allowing lower MAP (TTP) did not improve the primary outcome (30‑day days alive with normal lactate and without vasopressors/inotropes) compared with MAP-guided standard care. Mortality and organ-support–free days were similar and no excess safety signal emerged despite lower achieved MAP in the TTP arm.

Impact: Largest randomized test this week of a core resuscitation question—whether permissive lower MAP guided by perfusion indices improves outcomes—providing high-level evidence that outcome benefit was not observed and informing guideline deliberations.

Clinical Implications: Clinicians can incorporate peripheral perfusion measures (e.g., capillary refill) to tailor vasopressor intensity and avoid unnecessary high MAP targets when tissue perfusion is adequate, but routine adoption of a lower MAP target to improve outcomes is not supported by this trial alone.

Key Findings

  • Primary composite outcome (30-day days alive with normal lactate and without vasoactives) showed no difference between TTP and standard care.
  • 30-day mortality and organ-support–free days were comparable between arms; achieved MAP was lower in TTP but without excess safety events.
  • Trial informs timing/targeting of vasopressor therapy and encourages integration of bedside perfusion indices.

3. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990-2021: a cross-country systematic analysis with forecasts to 2050.

78.5
The Lancet. Public health · 2025PMID: 41082884

A multi-source modeling study estimated 380,000 AMR-associated deaths and 92,800 AMR-attributable deaths in the WHO Eastern Mediterranean Region in 2021, with six pathogens (including MRSA and major Gram-negatives) dominating burden and forecasts projecting substantial increases by 2050. The analysis highlights age and country heterogeneity and frames urgent priorities for surveillance, stewardship, and targeted interventions.

Impact: Delivers high-resolution, policy-relevant estimates and 2050 forecasts for regional AMR burden directly relevant to sepsis morbidity and mortality, guiding prioritization of stewardship, lab capacity building, and vaccination strategies in high-burden settings.

Clinical Implications: Health systems in the region should prioritize MRSA and Gram-negative control measures, expand microbiology capacity, and align stewardship/vaccination strategies to forecasted burden; globally, the study underscores the need to link AMR surveillance to sepsis care pathways.

Key Findings

  • Estimated 380,000 AMR-associated and 92,800 AMR-attributable deaths in the EMR in 2021, with marked age and country heterogeneity.
  • Six pathogens (S. pneumoniae, K. pneumoniae, E. coli, S. aureus, A. baumannii, P. aeruginosa) dominated burden; MRSA notable.
  • Forecasts project large increases by 2050 (AMR-attributable deaths ≈187,000; AMR-associated ≈752,000), emphasizing urgent mitigation needs.